VYNE Therapeutics Inc. (NASDAQ:VYNE – Get Free Report) declared a special dividend on Friday, July 10th. Shareholders of record on Wednesday, July 22nd will be given a dividend of 0.38 per share on Thursday, July 23rd. The ex-dividend date of this dividend is Wednesday, July 22nd.
VYNE Therapeutics Stock Performance
VYNE stock traded down $0.03 during trading on Friday, hitting $0.64. 16,004,494 shares of the company’s stock traded hands, compared to its average volume of 374,010. VYNE Therapeutics has a 52 week low of $0.28 and a 52 week high of $1.59. The stock has a market capitalization of $21.26 million, a price-to-earnings ratio of -1.68 and a beta of 2.00. The business has a fifty day simple moving average of $0.66 and a 200 day simple moving average of $0.62.
VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) last announced its earnings results on Friday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.10. The firm had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $0.20 million. VYNE Therapeutics had a negative net margin of 4,726.21% and a negative return on equity of 70.42%. Research analysts forecast that VYNE Therapeutics will post -1.1 earnings per share for the current fiscal year.
About VYNE Therapeutics
VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.
The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.
Further Reading
- Five stocks we like better than VYNE Therapeutics
- AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
- Micron’s $250 Billion Bet Could Reshape the AI Memory Race
- Rocket Lab’s Stock Drop Comes With a Bullish Twist
- Amazon’s New Debt Deal Puts Its AI Spending Story on Trial
Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
